NASDAQ:OMER Omeros (OMER) Stock Forecast, Price & News $2.77 -0.15 (-5.14%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$2.76▼$2.9250-Day Range$2.81▼$5.1452-Week Range$1.74▼$7.80Volume475,352 shsAverage Volume677,101 shsMarket Capitalization$174.12 millionP/E Ratio4.33Dividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Omeros MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside188.8% Upside$8.00 Price TargetShort InterestBearish20.06% of Float Sold ShortDividend StrengthN/ASustainability-1.30Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.10) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector397th out of 969 stocksPharmaceutical Preparations Industry167th out of 452 stocks 3.0 Analyst's Opinion Consensus RatingOmeros has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Omeros has a forecasted upside of 188.8% from its current price of $2.77.Amount of Analyst CoverageOmeros has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.06% of the float of Omeros has been sold short.Short Interest Ratio / Days to CoverOmeros has a short interest ratio ("days to cover") of 27.5, which indicates bearish sentiment.Change versus previous monthShort interest in Omeros has recently decreased by 0.08%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOmeros does not currently pay a dividend.Dividend GrowthOmeros does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOmeros has received a 67.78% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Omeros is -1.30. Previous Next 2.4 News and Social Media Coverage News SentimentOmeros has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Omeros this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Omeros to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omeros insiders have not sold or bought any company stock.Percentage Held by Insiders10.90% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.70% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Omeros are expected to grow in the coming year, from ($2.10) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omeros is 4.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Omeros is 4.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 107.93.Price to Book Value per Share RatioOmeros has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Omeros (NASDAQ:OMER) StockOmeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Read More OMER Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMER Stock News HeadlinesAugust 24, 2023 | msn.comOmeros: Where Medical Hopes Tangle With Fiscal RopesAugust 23, 2023 | msn.comOmeros: Betting Big On Narsoplimab, We Are Still A BuyerOctober 2, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.August 15, 2023 | finance.yahoo.comInstitutions own 40% of Omeros Corporation (NASDAQ:OMER) shares but individual investors control 56% of the companyAugust 9, 2023 | msn.comOmeros GAAP EPS of -$0.70 misses by $0.13August 9, 2023 | finance.yahoo.comOmeros Corporation Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | seekingalpha.comOmeros Q2 2023 Earnings PreviewAugust 4, 2023 | finance.yahoo.comOmeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023October 2, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.July 25, 2023 | money.usnews.comOmeros CorporationJune 26, 2023 | finance.yahoo.comMonoclonal Antibodies Industry Analysis 2023: 180+ Companies, 230+ Drugs, Therapeutics Assessment, Inactive Pipeline Products, Unmet NeedsJune 23, 2023 | finance.yahoo.comGlobal Monoclonal Antibodies Market Landscape Assessment 2023: Developments, Trends, Competitors and ProductsJune 12, 2023 | finance.yahoo.comOmeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association CongressJune 12, 2023 | finance.yahoo.comWhy Shares of Omeros Dropped on MondayJune 1, 2023 | seekingalpha.comOMER, TWST and RXTR are among after hour moversJune 1, 2023 | finance.yahoo.comOmeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) CongressMay 17, 2023 | msn.comUnusual Call Option Trade in Omeros (OMER) Worth $30.00KMay 16, 2023 | msn.comOmeros: Q1 Earning Overview, Best Contrarian Biotech Play Of 2023May 11, 2023 | msn.comOmeros Q1 2023 Earnings PreviewMay 11, 2023 | msn.comEarnings Preview: OmerosMay 11, 2023 | apnews.comOmeros: Q1 Earnings SnapshotMay 11, 2023 | msn.comOmeros: Q1 Earnings InsightsMay 10, 2023 | benzinga.comOmeros Stock (NASDAQ:OMER), DividendsMay 9, 2023 | finance.yahoo.comOmeros Corporation Reports First Quarter 2023 Financial ResultsMay 4, 2023 | finance.yahoo.comOmeros Corporation to Announce First Quarter Financial Results on May 9, 2023April 25, 2023 | finance.yahoo.comOmeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal HemoglobinuriaApril 12, 2023 | bizjournals.comOmeros lands $6.7M grant to test treatment for cocaine addictionSee More Headlines Receive OMER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter. Email Address OMER Company Calendar Last Earnings8/09/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:OMER CUSIP68214310 CIK1285819 Webwww.omeros.com Phone(206) 676-5000Fax206-676-5005Employees196Year Founded1994Price Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+174.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.64 Trailing P/E Ratio4.56 Forward P/E RatioN/A P/E GrowthN/ANet Income$47.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-643.87% Return on Assets-34.61% Debt Debt-to-Equity Ratio10.80 Current Ratio2.71 Quick Ratio2.71 Sales & Book Value Annual Sales$73.81 million Price / Sales2.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book2.13Miscellaneous Outstanding Shares62,860,000Free Float56,005,000Market Cap$183.55 million OptionableOptionable Beta0.99 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Gregory A. Demopulos M.D. (Age 64)Co-Founder, Chairman, CEO & Pres Comp: $1.79MMr. Michael A. Jacobsen (Age 65)Chief Accounting Officer, VP of Fin. & Treasurer Comp: $518.6kMr. Peter B. Cancelmo J.D. (Age 44)VP, Gen. Counsel & Corp. Sec. Comp: $503.24kDr. Pamela Pierce Palmer M.D. (Age 60)Ph.D., Co-Founder Dr. George A. Gaitanaris M.D. (Age 66)Ph.D., Chief Scientific Officer & VP of Science Mr. Peter W. Williams (Age 55)VP of HR Dr. J. Steven Whitaker J.D. (Age 67)M.D., VP of Clinical Devel. & Chief Medical Officer Dr. Catherine A. Melfi Ph.D. (Age 64)Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems Ms. Nadia Dac (Age 53)VP & Chief Commercial Officer Ms. Debra K. Bowes M.T (Age 63)VP & Chief Bus. Devel. Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRAssembly BiosciencesNASDAQ:ASMBMerrimack PharmaceuticalsNASDAQ:MACKGossamer BioNASDAQ:GOSSRallybioNASDAQ:RLYBView All CompetitorsInsiders & InstitutionsBarclays PLCSold 50,233 shares on 9/21/2023Ownership: 0.048%Farther Finance Advisors LLCBought 6,000 shares on 9/12/2023Ownership: 0.010%Wolverine Trading LLCSold 5,600 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemBought 20,251 shares on 8/21/2023Ownership: 0.032%Osaic Holdings Inc.Sold 10,712 shares on 8/21/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions OMER Stock - Frequently Asked Questions Should I buy or sell Omeros stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares. View OMER analyst ratings or view top-rated stocks. What is Omeros' stock price forecast for 2023? 3 brokers have issued twelve-month price objectives for Omeros' shares. Their OMER share price forecasts range from $3.00 to $13.00. On average, they anticipate the company's share price to reach $8.00 in the next year. This suggests a possible upside of 174.0% from the stock's current price. View analysts price targets for OMER or view top-rated stocks among Wall Street analysts. How have OMER shares performed in 2023? Omeros' stock was trading at $2.26 at the start of the year. Since then, OMER shares have increased by 29.2% and is now trading at $2.92. View the best growth stocks for 2023 here. When is Omeros' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our OMER earnings forecast. How were Omeros' earnings last quarter? Omeros Co. (NASDAQ:OMER) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.10. What is Gregory A. Demopulos' approval rating as Omeros' CEO? 17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees. What other stocks do shareholders of Omeros own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Technologies (ARRY), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Alibaba Group (BABA), Sangamo Therapeutics (SGMO), Verastem (VSTM), Bausch Health Companies (BHC) and Celldex Therapeutics (CLDX). What is Omeros' stock symbol? Omeros trades on the NASDAQ under the ticker symbol "OMER." How do I buy shares of Omeros? Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Omeros' stock price today? One share of OMER stock can currently be purchased for approximately $2.92. How much money does Omeros make? Omeros (NASDAQ:OMER) has a market capitalization of $183.55 million and generates $73.81 million in revenue each year. The biopharmaceutical company earns $47.42 million in net income (profit) each year or $0.64 on an earnings per share basis. How many employees does Omeros have? The company employs 196 workers across the globe. Does Omeros have any subsidiaries? The following companies are subsidiares of Omeros: Nura.Read More How can I contact Omeros? Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The official website for the company is www.omeros.com. The biopharmaceutical company can be reached via phone at (206) 676-5000, via email at ir@omeros.com, or via fax at 206-676-5005. This page (NASDAQ:OMER) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.